Currently available golden standard diagnostic methods of bladder cancer (BC) are cystoscopy and urinary cytology, which are also used for patient surveillance. Our aim is to find new specific, cost-effective non-invasive biomarkers, which can be used for early detection of bladder cancer. During the project will be collected clinical data and discovered new microRNA panels for low and high grade bladder cancer diagnostics. The miRNA profile in urine exosomes with potential influence on progression will be identified. The project will result in the discovery of new biomarkers that could be implemented in everyday medical practice in near future. This could change screening, therapy and observation algorithms for bladder tumor in existing guidelines that would allow early diagnosis of bladder cancer by providing more effective treatments with better prognosis and reducing the wide range of invalidating operations. This would improve the quality of life and maintain the ability to work for a large number of patients who will be able to continue to work and fully integrate into society. The economic burden of the country will be reduced, as the cost of treatment will be reduced due to a decrease in number of patients with advanced cancer who need palliative care, treatment costs will be reduced. For the better results the public will be widely informed in the press, television and social networks about the early detection of bladder cancer.
|Effective start/end date||1/12/20 → 31/12/21|
- Bladder tumour
Field of Science
- 3.2 Clinical medicine
Smart Specialization Area
- Biomedicine, medical technologies and biotechnology